SOM Biotech announces a presentation of the Phase 2 clinical results of SOM3355 for the treatment of chorea in Huntington´s disease

SOM Biotech will present results from the Phase 2 clinical study of SOM3355 for the treatment of chorea symptoms in Huntington´s disease at the XXVI World Congress on Parkinson’s Disease and Related Disorders, to be held May 1^st – 4^th 2021.

The International Association for Parkinsonism and Related Disorders (IAPRD) has accepted the abstract for the poster presentation at the IAPRD Congress 2021. The abstract is entitled “Proof-of-concept study testing SOM3355 (bevantolol) as a VMAT2 inhibitor to treat chorea symptoms in Huntington’s disease (HD)” and outlines data demonstrating that SOM3355 reduces chorea safely and efficaciously.

Aileen Ferré, SOM3355 Project Leader at SOM Biotech highlights: “We are pleased to share our findings on the efficacy of SOM3355 for the treatment of chorea movements in HD. Huntington’s chorea is a devastating condition. The involuntary abrupt movements mostly affect the arms and legs and facial muscles at even the early stages of the disease but also interferes with speech, swallowing, and other motor activities which adversely affects daily living and working. Finding an effective treatment for chorea is essential to help patients improve their quality of life.”